Which new interventions are now available on the NHS?
NHS England has approved the funding of 14 interventions, including surgeries to relieve the pain of pancreatitis and the symptoms of cerebral palsy; drugs for osteoporosis, cancer and hypercholesterolemia and an implant for those at risk from stroke.
The majority went through a relative prioritisation process, but some treatments were judged to have a low budget impact, to be cost neutral or cost-saving so were funded without testing. The funded interventions are:
- anakinra and tocilizumab for adult onset stills disease
- anakinra to treat periodic fevers and auto-inflammatory diseases (all ages)
- bendamustine with rituximab for first line treatment of advanced indolent non-hodgkins lymphoma
- bendamustine with rituximab for first line treatment of mantle cell lymphoma in adults
- bendamustine with rituximab for the treatment of relapsed mantle cell lymphoma
- emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors
- keraprosthesis for corneal blindness
- left atrial appendage occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)
- lomitapide for homozygous familial hypercholesterolemia
- selective dorsal rhizotomy
- service specification DNA nucleotide excision repair disorders services.
- susoctocog alfa for acquired haemophilia A
- teriparatide for osteoporosis in men
- total pancreatectomy with islet transplantation for chronic pancreatitis
Three further treatments will be considered again in November and could be available in 2019/20 if funding is approved:
- everolimus for refractory seizures associated with tuberous sclerosis complex
- human coagulation factor X for hereditary factor X deficiency
- selexipag for pulmonary arterial hypertension.
NHS England: Thousands of patients to benefit from innovative new treatments on the NHS
(Includes links to the clinical commissioning policy statements)